JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2002; 39:1951-1955
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Franz Alber, H.
Right arrow Articles by Weidinger, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Franz Alber, H.
Right arrow Articles by Weidinger, F.

CLINICAL STUDY

Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease

Hannes Franz Alber, MD*, Jozef Dulak, PhD*{dagger}, Matthias Frick, MD*, Wolfgang Dichtl, MD*, Severin Paul Schwarzacher, MD, FACC*, Otmar Pachinger, MD* and Franz Weidinger, MD*,*

* Division of Cardiology, Department of Internal Medicine, University of Innsbruck, Innsbruck, Austria
{dagger} Department of Cell Biochemistry, Institute of Molecular Biology, Jagiellonian University, Krakow, Poland

Manuscript received October 31, 2001; revised manuscript received March 4, 2002, accepted March 15, 2002.

* Reprint requests and correspondence: Dr. Franz Weidinger, Division of Cardiology, Department of Internal Medicine, University of Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria.

OBJECTIVES: The aim of this study was to test a possible influence of atorvastatin on the production of vascular endothelial growth factor (VEGF) in patients with coronary artery disease (CAD) and in vitro.

BACKGROUND: Vascular endothelial growth factor is suggested to be involved in the growth of atherosclerotic plaque by inducing its neovascularization. Hepatic hydroxymethyl glutaryl-coenzyme A reductase inhibitors (statins) are known to have atheroprotective effects beyond lipid lowering.

METHODS: Blood was collected from 14 male hypercholesterolemic patients with angiographically confirmed CAD at baseline and after two months of atorvastatin therapy (20 mg/d) and from eight male control patients. In an ex vivo assay, human coronary artery smooth muscle cells (HCASMC) were incubated with the patient plasma collected before and after atorvastatin therapy. To test the direct effect of atorvastatin on VEGF synthesis in vitro, HCASMC were treated with atorvastatin (1, 3 and 10 µM). The VEGF concentration was measured by enzyme-linked immunosorbent assay.

RESULTS: Atorvastatin therapy reduced VEGF plasma levels in CAD patients (from 31.1 ± 6.1 to 19.0 ± 3.6 pg/ml; p < 0.05). The VEGF plasma concentration tended to be higher in CAD patients before treatment compared to control patients (31.1 ± 6.1 vs. 23.4 ± 3.6 pg/ml; p = NS). Plasma collected before therapy induced significantly more VEGF in HCASMC compared to the plasma collected after treatment and compared to control cells. In vitro, atorvastatin decreased both the basal and the interleukin-1ß-induced VEGF release in HCASMC.

CONCLUSIONS: These data suggest that atorvastatin may lower the plasma level of VEGF in CAD patients, which could represent a novel beneficial effect of this and perhaps other statins.

Abbreviations and Acronyms
  CAD
  coronary artery disease
  DMSO
  dimethyl sulfoxide
  EDTA
  ethylenediamine-tetraacetic acid
  ELISA
  enzyme-linked immunosorbent assay
  FCS
  fetal calf serum
  HCASMC
  human coronary artery smooth muscle cells
  IL
  interleukin
  LDH
  lactate dehydrogenase
  LDL
  low-density lipoprotein
  VEGF
  vascular endothelial growth factor




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
S. Anwaruddin, A. T. Askari, and E. J. Topol
Redefining Risk in Acute Coronary Syndromes Using Molecular Medicine
J. Am. Coll. Cardiol., January 23, 2007; 49(3): 279 - 289.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Y. Kodama, Y. Kitta, T. Nakamura, H. Takano, K. Umetani, D. Fujioka, Y. Saito, K.-i. Kawabata, J.-e. Obata, A. Mende, et al.
Atorvastatin Increases Plasma Soluble Fms-Like Tyrosine Kinase-1 and Decreases Vascular Endothelial Growth Factor and Placental Growth Factor in Association With Improvement of Ventricular Function in Acute Myocardial Infarction
J. Am. Coll. Cardiol., July 4, 2006; 48(1): 43 - 50.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
T.-S. Li, M. Takahashi, R. Suzuki, T. Kobayashi, H. Ito, A. Mikamo, and K. Hamano
Pravastatin Improves Remodeling and Cardiac Function After Myocardial Infarction by an Antiinflammatory Mechanism Rather than by the Induction of Angiogenesis
Ann. Thorac. Surg., June 1, 2006; 81(6): 2217 - 2225.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
H F Alber, M Frick, J Dulak, J Dorler, R-H Zwick, W Dichtl, O Pachinger, and F Weidinger
Vascular endothelial growth factor (VEGF) plasma concentrations in coronary artery disease
Heart, March 1, 2005; 91(3): 365 - 366.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
W. Dichtl, J. Dulak, M. Frick, H. F. Alber, S. P. Schwarzacher, M. P.S. Ares, J. Nilsson, O. Pachinger, and F. Weidinger
HMG-CoA Reductase Inhibitors Regulate Inflammatory Transcription Factors in Human Endothelial and Vascular Smooth Muscle Cells
Arterioscler. Thromb. Vasc. Biol., January 1, 2003; 23(1): 58 - 63.
[Abstract] [Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2002 by the American College of Cardiology Foundation.